ClinicalTrials.gg
CompletedNCT03794492Updated May 22, 2024

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

A Phase 4 interventional study of Mycophenolate mofetil 500mg Tab. or 250mg Cap. and Tacrolimus in Kidney Transplant, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
169
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab. or 250mg/Cap.) in Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients

Read the detailed description

This study is a multi-center, non-comparative and phase IV clinical trial that evaluates incidence of Donor-Specific Antibody for 36 months after kidney transplantation when administered with Tacrolimus, Mycophenolate mofetil, and corticosteroid

02

Conditions studied

  • Kidney Transplant
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Over 19 years old(male or female)
  2. Patients who are planning to receive a kidney from a deceased or a living unrelated/related donor
  3. Agreement with written

Exclusion criteria

Exclusion Criteria:

  1. Donor's HLA antigen matches recipient or the Degree of Mis-Match is 0
  2. Patients with high sensitization who need desensitization therapy
  3. Multi organ recipients or previous transplant with any organs
  4. Diagnosed with cancer within five years
  5. Patient who receive kidney from ABO incompatibility donor or Lymphocyte cross-match positive donor
  6. Patients who have positive , or Anti- test result
  7. At screening

    • Under treatment for active liver disease, or Over 3times upper than normal range of liver function test (T-, , ALT)
    • WBC\<2,500/mm3, \<50,000/mm3, ANC\<1,500/mm3
  8. Pregnant or lactating women
  9. In investigator's judgment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    Mycophenolate mofetil

    One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.

    Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap. · Drug: Tacrolimus · Drug: Methylprednisolone/prednisolone · Drug: Basiliximab

Interventions

  • - Orally, up to 1g BID(total 2g daily)

    Also known as: Myrept® Cap./Tab.

  • - Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml

  • DrugMethylprednisolone/prednisolone

    Drug pages: Methylprednisolone · Prednisolone

    - Methyprednisolone 500mg / Prednisolone 5mg

  • - IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)

06

What researchers measure

Primary outcomes

  1. DSA(Donor-specific Anti-HLA Antibody)

    Incidence of DSA(Donor-specific Anti-HLA Antibody) up to 36months after Kidney transplantation

    Time frame: 36 months

Secondary outcomes

  1. Incidence of composite efficacy failure

    The frequency and percentage of composite efficacy failure (Treated-BPAMR \& ACR, graft loss, death and follow-up loss)

    Time frame: 12, 24, 36months

07

Study locations

1 site
  • Ajou University Hospital
    Suwan, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jul 2022, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2019
First posted
Jan 7, 2019
StartActual
Mar 31, 2018
Primary completionActual
Jul 22, 2022
CompletionActual
Apr 27, 2023
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03794492
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Mar 31, 2018
Primary completion
Jul 22, 2022
Completion
Apr 27, 2023
Last update
May 22, 2024

Study contacts

Chang-Kwan Oh, Ph.D
study chair · Ajou University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Tacrolimus · Methylprednisolone · Prednisolone · Basiliximab

Start the discussion